Marike van der Leeden1,2, Rosalie J Huijsmans1, Edwin Geleijn1, Mariëtte de Rooij2, Inge R Konings3, Laurien M Buffart3,4, Joost Dekker1, Martijn M Stuiver5. 1. a Department of Rehabilitation Medicine , VU University Medical Center , Amsterdam , The Netherlands. 2. b Reade , Amsterdam Rehabilitation Research Centre , Amsterdam , The Netherlands. 3. c Department of Medical Oncology , VU University Medical Center-Cancer Center Amsterdam , Amsterdam , The Netherlands. 4. d Department of Epidemiology and Biostatistics , VU University Medical Center , Amsterdam , The Netherlands. 5. e Department of Physiotherapy , Netherlands Cancer Institute , Amsterdam , The Netherlands.
Abstract
PURPOSE: Delivery of exercise interventions to patients with early-stage breast cancer undergoing chemotherapy requires complex clinical decisions. The purpose of this study was to develop a framework to support clinical decisions for tailoring exercise interventions to common comorbidities and cancer treatment-induced adverse effects. METHOD: Tailored exercise prescriptions were developed in four steps, following the i3-S strategy. All steps were based on current best available evidence, complemented with expert opinions. First, common comorbidities and treatment-induced adverse effects were identified. In the subsequent steps, contra-indications and restrictions for exercise were described, along with possible exercise adaptations. In the final step, the obtained information was synthesized into a framework. RESULTS: Prevalent comorbidities were hypertension, heart disease, diabetes mellitus, (osteo)arthritis, chronic obstructive pulmonary disease, and obesity. Adverse effects included conditions induced by pretreatment (e.g., lymphedema as a result of surgery) or by chemotherapy (e.g., reduced blood cell counts). Adaptations to the recommended exercise program were related to exercise tolerance, safety, and hygiene. A framework was proposed to guide clinical decisions during the exercise intervention. CONCLUSION: Comorbidities and adverse effects of breast cancer treatment require exercise adaptations. The proposed framework provides guidance on tailored exercise prescriptions in patients with breast cancer undergoing chemotherapy. Implications for Rehabilitation Exercise is recommended for patients with breast cancer undergoing chemotherapy, but requires complex clinical decisions of the health professional. We identified the most important comorbidities and adverse effects of breast cancer treatment, and the resultant contra-indications and restrictions to exercise. We incorporated these findings into a clinical decision framework that provides suggestions for exercise adaptations in patients with breast cancer undergoing chemotherapy.
PURPOSE: Delivery of exercise interventions to patients with early-stage breast cancer undergoing chemotherapy requires complex clinical decisions. The purpose of this study was to develop a framework to support clinical decisions for tailoring exercise interventions to common comorbidities and cancer treatment-induced adverse effects. METHOD: Tailored exercise prescriptions were developed in four steps, following the i3-S strategy. All steps were based on current best available evidence, complemented with expert opinions. First, common comorbidities and treatment-induced adverse effects were identified. In the subsequent steps, contra-indications and restrictions for exercise were described, along with possible exercise adaptations. In the final step, the obtained information was synthesized into a framework. RESULTS: Prevalent comorbidities were hypertension, heart disease, diabetes mellitus, (osteo)arthritis, chronic obstructive pulmonary disease, and obesity. Adverse effects included conditions induced by pretreatment (e.g., lymphedema as a result of surgery) or by chemotherapy (e.g., reduced blood cell counts). Adaptations to the recommended exercise program were related to exercise tolerance, safety, and hygiene. A framework was proposed to guide clinical decisions during the exercise intervention. CONCLUSION: Comorbidities and adverse effects of breast cancer treatment require exercise adaptations. The proposed framework provides guidance on tailored exercise prescriptions in patients with breast cancer undergoing chemotherapy. Implications for Rehabilitation Exercise is recommended for patients with breast cancer undergoing chemotherapy, but requires complex clinical decisions of the health professional. We identified the most important comorbidities and adverse effects of breast cancer treatment, and the resultant contra-indications and restrictions to exercise. We incorporated these findings into a clinical decision framework that provides suggestions for exercise adaptations in patients with breast cancer undergoing chemotherapy.
Entities:
Keywords:
Exercise; adverse effects; breast cancer; chemotherapy; clinical decisions; comorbidity
Authors: Maike G Sweegers; Laurien M Buffart; Wouke M van Veldhuizen; Edwin Geleijn; Henk M W Verheul; Johannes Brug; Mai J M Chinapaw; Teatske M Altenburg Journal: Oncologist Date: 2018-11-13
Authors: Cosima Zemlin; Caroline Stuhlert; Julia Theresa Schleicher; Carolin Wörmann; Laura Altmayer; Marina Lang; Laura-Sophie Scherer; Ida Clara Thul; Carolin Müller; Elisabeth Kaiser; Regine Stutz; Sybelle Goedicke-Fritz; Laura Ketter; Michael Zemlin; Gudrun Wagenpfeil; Georges Steffgen; Erich-Franz Solomayer Journal: Front Oncol Date: 2021-10-19 Impact factor: 6.244
Authors: Nicole L Stout; Justin C Brown; Anna L Schwartz; Timothy F Marshall; Anna M Campbell; Larissa Nekhlyudov; David S Zucker; Karen M Basen-Engquist; Grace Campbell; Jeffrey Meyerhardt; Andrea L Cheville; Kelley R Covington; Jennifer A Ligibel; Jonas M Sokolof; Kathryn H Schmitz; Catherine M Alfano Journal: Cancer Date: 2020-03-25 Impact factor: 6.860
Authors: Mohammad Keilani; Franz Kainberger; Anna Pataraia; Timothy Hasenöhrl; Barbara Wagner; Stefano Palma; Fadime Cenik; Richard Crevenna Journal: Wien Klin Wochenschr Date: 2019-07-02 Impact factor: 1.704
Authors: Miguel S Conceição; Sophie Derchain; Felipe Cassaro Vechin; Guilherme Telles; Guilherme Fiori Maginador; Luís Otávio Sarian; Cleiton Augusto Libardi; Carlos Ugrinowitsch Journal: Front Physiol Date: 2021-06-25 Impact factor: 4.566
Authors: Laurien M Buffart; Remco de Bree; Martine Altena; Sophie van der Werff; Constance H C Drossaert; Caroline M Speksnijder; Michiel W van den Brekel; Harriët Jager-Wittenaar; Neil K Aaronson; Martijn M Stuiver Journal: Support Care Cancer Date: 2017-11-18 Impact factor: 3.603